In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4453-4456

  Di Bonaventura, Giovanni ^a   Spedicato, Ilaria ^a   Picciani, Carla ^a   D'Antonio, Domenico ^b   Piccolomini, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD CULTURE; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA LUSITANIAE; CANDIDIASIS; DOSE RESPONSE; FUNGICIDAL ACTIVITY; FUNGISTASIS; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TIME KILL AND POSTANTIFUNGAL EFFECT;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COLONY COUNT, MICROBIAL; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 7244236513     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4453-4456.2004     Document Type: Article

References (25)

1. Cheng, M. F., K. W. Yu, R. B. Tang, Y. H. Fan, Y. L. Yang, K. S. Hsieh, M. Ho, and H. J. Lo. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48:33-37.
2. Chryssanthou, E., O. Cars, and J. Sjölin. 2002. New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve. Antimicrob. Agents Chemother. 46:4016-4018.
3. Clancy, C., M. Nguyen, and V. Yu. 1996. Fungemia caused by Candida lusitaniae. Infect. Med. 13:940, 948-951.
4. Collin, B., C. J. Clancy, and M. H. Nguyen, 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Updat. 2:9-14.
5. Dick, J. D., R. R. Rosengard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saval. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Intern. Med. 102:67-68.
6. Ernst, E. J., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111.
7. Ernst, E. J., K. Yodoi, and M. E. Klepser. 2002. Rates and extent of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob. Agents Chemother. 46:578-581.
8. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, N. Holliday, and S. B. Killian. 2004. Multicenter comparison of Sensitre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
9. Favel, A., A. Michel-Nguyen, A. Dairy, S. Challier, F. Leclerc, C. Chastin, K. Fallague, and P. Regli. 2004. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J. Antimicrob. Chemother. 53: 526-529. (Advance Access published 12 February 2004.)
10. Groll, A. H., and T. J. Walsh. 2002. Invasive fungal infections in the neutropenic cancer patient: current approaches and future strategies. Infect. Med. 19:326-334.
11. Hadfield, T. L., M. B. Smith, R. E. Winn, M. G. Rinaldi, and C. Guerra. 1987. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9:1006-1012.
12. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:402-478.
13. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
14. Krcmery, V., and A. J. Barnes. 2002. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50:243-260.
15. Manavathu, E. K., J. L. Cutright, and P. H. Chandrasekar. 1998. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 42: 3018-3021.
16. Maxwell, M. J., S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, D. J. Diekema, M. A. Pfaller, and the International Fungal Surveillance Participant Group. 2003. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:1087-1090.
17. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J, Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
19. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, R. N. Jones, and the International Fungal Surveillance Participant Group. 2003. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:78-83.
20. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2003. Caspofungin activity against clinical isolates of fluconazole-resistant Candida, J. Clin. Microbiol. 41:5729-5731.
21. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp. including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
22. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, and R. N. Jones. 2004. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48:101-105.
23. Schwartz, S., D. Milatovic, and E. Thiel. 1997. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br. J. Hematol. 97:663-665.
24. Summers, K. K., T. C. Hardin, S. J. Gore, and J. R. Graybill. 1997. Therapeutic drug monitoring of systemic antifungal therapy. J. Antimicrob. Chemother. 40:753-764.
25. Turnidge, J. D., S. Gudmundsson, B. Vogelman, and W. A. Craig. 1994. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34:83-92.